<DOC>
	<DOCNO>NCT01227746</DOCNO>
	<brief_summary>Imatinib current standard treatment advanced GIST . Previous study show GIST genotype associate treatment outcome exon 11 superior outcome compare exon 9 WT.10 , 11 In patient exon 9 kit mutation , response rate high imatinib give 800mg daily compare standard dose 400mg daily . Although data link tyrosine kinase mutation status imatinib response metastatic GISTs intriguing , information need mutation test adopt part routine analysis high-risk overtly malignant KIT-expressing GISTs.25 Despite fact exon 9 mutation associate low response rate , overall survival appear good high-dose therapy . The investigator propose conduct retrospective analysis mutational analysis patient GIST determine relationship patient response imatinib dose .</brief_summary>
	<brief_title>A Retrospective Study C-kit Mutation Status Asian Patients With Advanced Gastro-intestinal Stromal Tumors ( GIST ) Treated With Imatinib .</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>1 . Histologic diagnosis advance stage metastatic GIST 2 . Asian patient ( defined investigator ) 3 . First line treatment imatinib 4 . Availability tumor sample kit mutation analysis 5 . Availability tumor response rate time progression data</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Advanced gastro-intestinal stromal tumor</keyword>
</DOC>